1. Scrip
  2. >>Business
  3. >>Deals

Alapis buys veterinary distributor in Cyprus

 
• By Maria Bailey

Alapis, a rapidly developing Greek company that operates in human and animal pharmaceuticals, has acquired 100% of the shares of Pharmacare, a distributor of veterinary products, for €950,000. Pharmacare, which was established in 1988 in Nicosia, Cyprus, distributes veterinary products on the local market for a number of companies includingBayer, Lohmann Animal Health, Boehringer Ingelheimand Danisco. It reported sales of €1.8 million and earnings before interest, taxes, depreciation and amortisation of €434,000 last year. Pharmacare will incorporate all of Alapis’s operations in Cyprus, currently carried out by Alapis Pharma, its local subsidiary.

Alapis, a rapidly developing Greek company that operates in human and animal pharmaceuticals, has acquired 100% of the shares of Pharmacare, a distributor of veterinary products, for €950,000. Pharmacare, which was established in 1988 in Nicosia, Cyprus, distributes veterinary products on the local market for a number of companies includingBayer, Lohmann Animal Health, Boehringer Ingelheimand Danisco. It reported sales of €1.8 million and earnings before interest, taxes, depreciation and amortisation of €434,000 last year. Pharmacare will incorporate all of Alapis’s operations in Cyprus, currently carried out by Alapis Pharma, its local subsidiary.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

More from Business

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.